tiprankstipranks
Biocryst Pharmaceuticals (DE:BO1)
FRANKFURT:BO1
Holding DE:BO1?
Track your performance easily

BioCryst (BO1) Income Statement

1 Followers

BioCryst Income Statement

Last quarter (Q3 2024), BioCryst's total revenue was $117.08M, an increase of 34.98% from the same quarter last year. In Q3, BioCryst's net income was $-14.03M. See BioCryst’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 412.58M$ 331.41M$ 270.83M$ 157.17M$ 17.81M$ 48.84M
Cost of Revenue
$ 7.98M$ 4.66M$ 6.59M$ 7.26M$ 1.68M$ 3.73M
Gross Profit
$ 404.60M$ 326.75M$ 264.23M$ 149.91M$ 16.14M$ 45.11M
Operating Expense
$ 445.29M$ 430.46M$ 412.67M$ 327.63M$ 190.89M$ 144.56M
Operating Income
$ -40.70M$ -103.71M$ -148.44M$ -177.72M$ -174.76M$ -99.45M
Net Non Operating Interest Income Expense
$ -62.65M$ 92.46M$ 93.97M$ -59.29M$ -14.50M$ -11.89M
Other Income Expense
-$ -30.06M$ -1.98M$ -55.84M$ 2.01M-
Pretax Income
$ -124.13M$ -226.23M$ -244.38M$ -181.81M$ -182.81M$ -110.83M
Tax Provision
$ -308.00K$ 310.00K$ 2.73M$ 2.25M$ -2.54M$ -1.59M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -123.82M$ -226.54M$ -247.12M$ -184.06M$ -191.98M$ -108.90M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 453.02M$ 435.12M$ 419.26M$ 334.86M$ 192.44M$ 148.29M
Net Income From Continuing And Discontinued Operation
$ -123.82M$ -226.54M$ -247.12M$ -184.06M$ -182.81M$ -108.90M
Normalized Income
$ -25.69M-----
Interest Expense
------
EBIT
$ -25.48M$ -117.99M$ -145.29M$ -122.52M$ -168.31M$ -98.94M
EBITDA
$ -24.11M$ -116.33M$ -143.85M$ -121.74M$ -167.56M$ -96.82M
Currency in USD

BioCryst Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis